FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

WHITEHOUSE STATION, New Jersey—FDA has granted priority review status to Merck's New Drug Application for Zolinza (vorinostat, also known as suberoylanilide hydroxamic acid or SAHA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL). A pivotal phase IIb trial showed activity in CTCL patients who had failed a median of three previous therapies. Zolinza is potentially the first in a new class of therapies, the histone deacetylase inhibitors.

Related Videos
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Related Content